2023-03-28 ヒューストン大学(UH)
Pfizerの抗ウイルス治療薬Paxlovidは、症状が現れてから3日以内にしか有用ではありませんが、この可能性のある新しい薬剤は、暴露後にウイルスの感染期間を短縮することができます。
<関連情報>
- https://uh.edu/news-events/stories/2023/march-2023/03282023-mcconnell-covid-medicine-shortens-course.php
- https://www.mdpi.com/2227-9059/11/3/916/htm
SARS-CoV-2およびその最も感染力の強い変異体であるDelta、Omicronの感染をin vitroで中和する低分子化合物について A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron
Arfaxad Reyes-Alcaraz,Hanan Qasim,Elizabeth Merlinsky,Glenn Fox,Tasneem Islam,Bryan Medina,Robert J. Schwartz,John W. Craft, Jr. and Bradley K. McConnell
Biomedicines Published: 15 March 2023
DOI:https://doi.org/10.3390/biomedicines11030916
Abstract
The COVID-19 pandemic has underscored the urgent need to develop highly potent and safe medications that are complementary to the role of vaccines. Specifically, it has exhibited the need for orally bioavailable broad-spectrum antivirals that are able to be quickly deployed against newly emerging viral pathogens. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and its variants Delta and Omicron are still a major threat to patients of all ages. In this brief report, we describe that the small molecule CD04872SC was able to neutralize SARS-CoV2 infection with a half-maximal effective concentration (EC50) = 248 μM. Serendipitously, we also were able to observe that CD04872SC inhibited the infection of the SARS-CoV-2 variants; Delta (EC50 = 152 μM) and Omicron (EC50 = 308 μM). These properties may define CD04872SC as a potential broad-spectrum candidate lead for the development of treatments for COVID-19.
